AuntMinnie

FEBRUARY 12, 2024

Chinese clinicians have provided evidence in a “real-world study” that shows amyloid PET imaging is effective for diagnosing and managing patients with Alzheimer’s disease, according to a study published February 8 in Alzheimer’s and Dementia. of patients, noted lead author Ke-Liang Chen, MD, a neurologist at Fudan University.

PET Scan 104

PET Scan Diagnose Disease Radiopharmaceuticals 104

Imaging Technology

OCTOBER 5, 2023

Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Recently approved by the U.S. on behalf of Gary A.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

Imaging Technology

AUGUST 29, 2023

Alan Taylor , stated, “Large-scale manufacture of therapeutic Cu-67 from highly efficient, environmentally preferable electron accelerators is critical to overcome the widespread supply issues in the radiopharmaceutical industry, due to a heavy reliance on a small number of antiquated nuclear reactors.

Pharmaceutical 97

Pharmaceutical Radiopharmaceuticals Clinic Medical 97

AuntMinnie

MARCH 25, 2024

PET/CT is poised to become a key tool for imaging the coronary arteries – a clinical imaging exam that can reveal early warning signs of fatal conditions when patients present with symptoms of chest pain, experts say. Coronary artery disease (CAD) is the leading cause of mortality in the U.S.

Nuclear Medicine 128

Nuclear Medicine Radiopharmaceuticals Disease Radiation 128

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology.

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

AuntMinnie

OCTOBER 2, 2024

The following is the list of candidates for the 2024 edition of the Minnies, AuntMinnie.com 's campaign to recognize the best and brightest in medical imaging. Image from Martin W. Image from Denis Le Bihan, PhD, of the NeuroSpin research facility, et al. Image from Richard Carson, PhD, of Yale University, et al.

Digital Imaging and Communications in Medicine 137

Digital Imaging and Communications in Medicine X-ray MRI Hospital 137

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

JANUARY 30, 2024

The timing of the new codes dovetails with advances in neuroimaging, such as in the assessment of white-matter diseases. Risk factors Michael Alosco, PhD, of Boston University and the Chobanian and Avedisian School of Medicine is among those contributing to brain imaging and white matter research.

MRI 105

MRI Radiopharmaceuticals Disease Imaging 105

Imaging Technology

JUNE 20, 2024

More than half of the world’s population is underserved and lacks access to essential health services, and two-thirds have no access to diagnostic imaging.

Healthcare 104

Healthcare Healthcare Nuclear Medicine Computed Tomography 104

Imaging Technology

JULY 28, 2023

It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology. We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. POSLUMA was approved by the U.S.

Diagnostic 98

Diagnostic Clinic Radiopharmaceuticals Radiation 98

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, Tucson, Ariz.,

Diagnostic 105

Diagnostic Radiation Oncology Radiation Clinic 105

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

Imaging Technology

JULY 20, 2023

He focuses on treating pediatric patients as well as adults diagnosed with brain, spine and other central nervous system tumors. Keole is a radiation oncologist at the Mayo Clinic in Scottsdale, Arizona and also sees patients at Phoenix Children’s Hospital.

Radiation Oncology 98

Radiation Oncology Radiation Government Community Practice 98

Imaging Technology

MAY 23, 2023

More than one million people receive radiation therapy each year to treat cancer and other diseases, yet ongoing cuts, prior authorization and rising costs threaten to undermine equitable access to this life-saving treatment. in the past three decades.

Radiation Oncology 96

Radiation Oncology Radiation Clinic Medicare 96

AuntMinnie

DECEMBER 8, 2023

Organizing pneumonia can hide underlying lung cancers in up to 10% of cases, and repeat imaging in the form of PET/CT -- and additional biopsy -- should be considered in patients with high clinical suspicion of malignancy, researchers have reported. Kim discussed a case that demonstrated how additional biopsy proved necessary.

Imaging 123

Imaging Radiopharmaceuticals Disease Diagnose 123

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98